Our Treatments

Put the power of a 24/7 tool in patients' hands.

Provide anytime, anywhere access to evidence-based approaches, like Cognitive Behavioral Therapy, Fluency Training, and Contingency Management, with the clinically-proven prescription digital therapeutic that meets their needs.1,2 

ABOUT reSET-O

reSET-O-logo-dark-gray
For individuals with opioid use disorder, reSET-O® is the only FDA-authorized prescription digital therapeutic that’s proven to help patients stay in treatment longer.3,1 It works in a way that meets patients where they already are, on their smartphones, so they can turn screen time into therapy time. Patients prescribed reSET-O download it to their phone for secure, discreet, convenient access to therapy, interactive learning, and support.
Play Video

ABOUT reSET

reSET-logo-dark-gray
A 12-week clinical study showed that patients using reSET were more than 2x more likely to abstain from substance use than those who didn't use reSET.2,*
*during the last 4 weeks of trial

For individuals with substance use disorder, reSET® is the first FDA-authorized prescription digital therapeutic that’s proven to increase abstinence and treatment retention.2,4 Patients prescribed reSET download it to their phone for secure, discreet, convenient access to therapy, interactive learning, and support. reSET lets them practice what you’ve taught them anytime, anywhere, and report daily triggers, cravings, and substance use—so they feel more engaged and supported between appointments, and you get a clearer picture of where they are in their recovery journey.2

Play Video

clinician dashboard

Optimize treatment and enrich sessions using real world patient data.1,2

next steps

See the process

Hear from HCPs and patients as they talk about the ways reSET-O and reSET are helping them stay connected, accountable and fully engaged in recovery.

Prescribing and support.

The PearConnect™ Service Center is all about helping you and your patients stay focused on treatment and recovery. Start here for flexible prescribing options, downloadable forms, tech assistance and more.

Experience reSET-O and reSET.

reSET-O

Indications for Use:

reSET-O prescription digital therapeutic is a 12-week (84 day) software application intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic.

Important Safety Information for Clinicians:

Warnings: reSET-O is intended for patients whose primary language is English and who have access to an Android/iOS tablet or smartphone. reSET-O is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

Clinicians should not use reSET-O to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET-O to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.

reSET-O is not intended to be used as a stand-alone therapy for Opioid Use Disorder (OUD). reSET-O does not replace care by a licensed medical practitioner. reSET-O does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider. The ability of reSET-O to prevent potential relapse after therapy discontinuation has not been studied.

The long-term benefit of reSET-O has not been evaluated in studies lasting beyond 12 weeks (84 days) in the OUD population. The ability of reSET-O to prevent potential relapse after therapy discontinuation has not been studied.

Please see the Clinician Brief Summary Instructions for reSET-O.

reSET

Indications for Use:

reSET is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients 18 years of age and older, who are currently enrolled in outpatient treatment under the supervision of a clinician. reSET is indicated as a 12-week (90 day) prescription-only treatment for patients with substance use disorder (SUD), who are not currently on opioid replacement therapy, who do not abuse alcohol solely, or who do not abuse opioids as their primary substance of abuse.

It is intended to:

  • increase abstinence from a patient’s substances of abuse during treatment, and
  • increase retention in the outpatient treatment program.

 

Important Safety Information for Clinicians:

Warnings: reSET is intended for patients whose primary language is English and who have access to an Android/iOS tablet or smartphone. reSET is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

Clinicians should not use reSET to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.

reSET is not intended to be used as a stand-alone therapy for substance use disorder (SUD). reSET does not replace care by a licensed medical practitioner. reSET does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.

The long-term benefit of treatment with reSET on abstinence has not been evaluated in studies lasting beyond 12 weeks (90 days) in the SUD population. The ability of reSET to prevent potential relapse after treatment discontinuation has not been studied.

Please see the Clinician Brief Summary Instructions for reSET.

 

References:

1. reSET-O Clinician directions for use. Pear Therapeutics, Inc. 2020.

2. reSET Clinician directions for use. Pear Therapeutics, Inc. 2020.

3. FDA clears mobile medical app to help those with opioid use disorder stay in recovery programs. News release. Silver Spring, MD: US Food and Drug Administration. December 10, 2018. Accessed May 18, 2020. https://www.fda.gov/news-events/press-announcements/fda-clears-mobile-medical-app-help-those-opioid-use-disorder-stay-recovery-programs

4. FDA permits marketing of mobile medical application for substance use disorder. News release. Silver Spring, MD: US Food and Drug Administration. September 14, 2017. Accessed May 18, 2020. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-mobile-medical-application-substance-use-disorder

This information is intended for US healthcare professionals. Please confirm you are a healthcare professional to continue.